CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 48 enrolled
Drug / intervention
AMG 529 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03170193
NCT03170193Phase 1Completed
CompareCT.gov

A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 529 in Healthy Subjects

Amgen·interventional·Posted May 30, 2017·Updated Jul 5, 2019

In Brief

A Phase 1 clinical trial evaluating AMG 529 and Placebo for Cardiovascular. Completed, enrolled 48 participants across 1 site.

Detailed Summary

A study to assess the safety and tolerability of AMG 529 following single, ascending doses administered subcutaneously (SC) or intravenously (IV) in healthy adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedMay 30, 2017
Enrollment StartMay 15, 2017
Primary CompletionNov 17, 2017
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 9.1 years ago

Interventions

AMG 529drug

Ascending single doses of AMG 529 by subcutaneous (SC) or intravenous (IV) injection

Placebodrug

Single doses of matching placebo by SC or IV injection